Trending...
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 143
- Logan Brothers Band brings their Country Rock sound to FLEventsandFestivals.com - 129
- Who Won Paris Fashion Week SS27? Dior Took About 45% of the Week's $795.6M in Earned Media Value - 113
USPTO allows 26 claims for ophthalmic formulations containing quaternary chitosan derivatives, marking a key step toward U.S. patent protection.
DALLAS - Floridant -- ClearSight Therapeutics Receives U.S. Patent Notice of Allowance for Ophthalmic Formulation Technology for unmet ocular diseases
Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications
DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."
The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.
More on The Floridant
"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."
"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."
In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.
More on The Floridant
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.
Media Contact
ClearSight Therapeutics
info@clearsighttx.com
972-983-7761
Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications
DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."
The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.
More on The Floridant
- New Website – Reduceregens.com
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
- Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
- Your Pad Thai Just Got a Stock Ticker
- Support hands-on agricultural education for children and families at upcoming gala
"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."
"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."
In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.
More on The Floridant
- Digital Brew Unveils New Brand Identity as It Evolves into an AI Optimization Agency
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
- Florida's Sunshine Tax, Measured: McDonald's Prices Run 2% Above the National Median
- Fort Myers Community Concert Association Announces 2027 Season Underwriter
- Florida Fresh Porta Potty Rentals Brings Portable Restroom and Restroom Trailer Rentals to Orlando
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.
Media Contact
ClearSight Therapeutics
info@clearsighttx.com
972-983-7761
Source: ClearSight Therapeutics, Inc.
0 Comments
Latest on The Floridant
- The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
- Bright MLS Tells RELTO the Staging Label Other Boards Require on the Photo Violates Its Rules
- Events by Dubsdread Explores the Art of Authenticity with New Feature on Unique Wedding Experiences
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
- Unified Essentials Launches Local SEO Guide for Florida Businesses
- Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
- Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
- Victor Robenson Launches Big Vic Empire LLC — Sports, Music, Entertainment, Business Consulting
- Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
- Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
- Runners pack the runway at Naples Airport for annual 5K, 10K
- Goldstein, Buckley law firm marks 20 years of collecting Toys for Tots donations
- Curran Young Construction names Brian Simper chief financial officer
- Holiday Picture Book "Sasquatch on a Stump" Delivers a Heartwarming Tale of Friendship and Christmas
- Harry Chapin Food Bank launches Smart Food Locker Program to expand access to nutritious f
- AmeriCare Home Health Services to transition to Avow brand
- AI Spots Dyslexia in Brain Scans With 96 Percent Accuracy? ADA Explains What the Study Shows
- Goodwill Southwest Florida Expands Retail Footprint and Community Impact
- Miyako Doral Celebrates Official Opening of Its New Pinecrest Location with Community Ribbon Cutting
- Islamorada Luxury Real Estate Forecast 2026-2027